CorMedix Inc. (CRMD)
NASDAQ: CRMD
· Real-Time Price · USD
12.42
-2.54 (-16.98%)
At close: Jun 27, 2025, 12:09 PM
-16.98% (1D)
| Bid | 12.41 |
| Market Cap | 842.38M |
| Revenue (ttm) | 82.55M |
| Net Income (ttm) | 17.18M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 49.68 |
| Forward PE | 10.78 |
| Analyst | Buy |
| Ask | 12.43 |
| Volume | 5,353,586 |
| Avg. Volume (20D) | 1,988,437.4 |
| Open | 12.86 |
| Previous Close | 14.96 |
| Day's Range | 12.27 - 13.00 |
| 52-Week Range | 3.61 - 17.43 |
| Beta | 1.61 |
About CRMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CRMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CRMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
CorMedix Inc. is scheduled to release its earnings on Aug 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 hours ago
CorMedix shares are trading lower after the compan...
Unlock content with
Pro Subscription
20 hours ago
-0.07%
CorMedix shares are trading lower after the company announced an $85 million public offering.
3 weeks ago · seekingalpha.com
CorMedix: DefenCath In Exponential Growth Phase With Robust Market PositionI am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, dri...
